[go: up one dir, main page]

UY27816A1 - Nueva combinacion - Google Patents

Nueva combinacion

Info

Publication number
UY27816A1
UY27816A1 UY27816A UY27816A UY27816A1 UY 27816 A1 UY27816 A1 UY 27816A1 UY 27816 A UY27816 A UY 27816A UY 27816 A UY27816 A UY 27816A UY 27816 A1 UY27816 A1 UY 27816A1
Authority
UY
Uruguay
Prior art keywords
new combination
inhibitor
pde5
cgmp
ace
Prior art date
Application number
UY27816A
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY27816A1 publication Critical patent/UY27816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las combinaciones que comprenden a) un inhibidor de fosfodiesterasa de tipo 5 (PDE5) específica de monofosfato de guanosina c´clico (GMPc) y b) un inhibidor de enzima de conversión de angiotensina (ACE) son útiles para tratar la hipertensión.
UY27816A 2002-05-23 2003-05-21 Nueva combinacion UY27816A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination

Publications (1)

Publication Number Publication Date
UY27816A1 true UY27816A1 (es) 2003-12-31

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27816A UY27816A1 (es) 2002-05-23 2003-05-21 Nueva combinacion

Country Status (18)

Country Link
EP (1) EP1506015A2 (es)
JP (1) JP2005529927A (es)
KR (1) KR20050004195A (es)
CN (1) CN1655820A (es)
AR (1) AR040090A1 (es)
AU (1) AU2003223071A1 (es)
BR (1) BR0311191A (es)
CA (1) CA2485984A1 (es)
IL (1) IL164975A0 (es)
MX (1) MXPA04010951A (es)
NO (1) NO20045517L (es)
PA (1) PA8574201A1 (es)
PE (1) PE20040514A1 (es)
PL (1) PL374198A1 (es)
RU (1) RU2004133973A (es)
TW (1) TW200407153A (es)
UY (1) UY27816A1 (es)
WO (1) WO2003099194A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
KR20090042863A (ko) 2006-08-24 2009-04-30 서피스 로직스, 인크. 약물동력학적으로 향상된 화합물
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP3865120B1 (en) 2013-07-19 2025-06-25 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DK1174431T3 (da) * 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
JP2003511452A (ja) * 1999-10-11 2003-03-25 ファイザー・インク ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
WO2003099194A3 (en) 2004-06-03
BR0311191A (pt) 2005-03-01
AU2003223071A1 (en) 2003-12-12
MXPA04010951A (es) 2005-06-08
IL164975A0 (en) 2005-12-18
RU2004133973A (ru) 2005-09-10
KR20050004195A (ko) 2005-01-12
TW200407153A (en) 2004-05-16
PL374198A1 (en) 2005-10-03
EP1506015A2 (en) 2005-02-16
PA8574201A1 (es) 2003-12-19
CN1655820A (zh) 2005-08-17
PE20040514A1 (es) 2004-08-24
JP2005529927A (ja) 2005-10-06
WO2003099194A2 (en) 2003-12-04
CA2485984A1 (en) 2003-12-04
AR040090A1 (es) 2005-03-16
NO20045517L (no) 2004-12-17

Similar Documents

Publication Publication Date Title
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
UY27816A1 (es) Nueva combinacion
ECSP034519A (es) Inhibidores de xantina fosfodiesterasa v
DK1440709T3 (da) Kombinationer, der omfatter cGMP PDE5 inhibitorer
IS6689A (is) Forlyf af fosfónat-kirna hliðstæðum og aðferð tilað velja og búa þær til
IL162728A0 (en) Methods of inducing differentiationin stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem c
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
FI20001017L (fi) Näppäimistön valaisujärjestely, joka mahdollistaa näppäinten muuttuvan ja yksilöllisen valaisemisen, sekä menetelmä sen käyttämiseksi
TR200102883T2 (tr) Otolog transplantasyon için yöntem, alet ve alet takımı.
AR031050A1 (es) Estropajo de mano
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
BR9710570A (pt) Inibidor de adesão de células
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ES2179355T3 (es) Derivados de tiazol utilizados como inhibidores de proteina quinasa c.
EP1482916A4 (en) SCHWANNZELLEN AND PHOSPHODIESTERASE-HEMMER BASED THERAPY
ATE234091T1 (de) Thrombin inhibitoren
GT200300231A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
PA8575501A1 (es) Nueva combinacion
UY27813A1 (es) Inhibidores de la peptido-desformilasa
IT244715Y1 (it) Caricatore per pistola chiodatrice ad aria compressa .
EP1496897A4 (en) Tyrosine kinase inhibitor
ES2168816T3 (es) Cemento de inyeccion que contiene inhibidores de la corrosion.
DOP2003000645A (es) Nueva combinacion
ATE335824T1 (de) Isolierte luziferasen sowie deren verwendung
DE60136573D1 (de) Gewebefixativzusammensetzung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520